Abstract
We sincerely appreciate the interest expressed in our meta-analysis on the role of cytoreductive surgery in advanced and recurrent endometrial cancer [1], and we welcome the opportunity to discuss it further with regard to the appropriate place for neoadjuvant chemotherapy in patients with advanced endometrial cancer. The authors point out that their series of 24 patients receiving neoadjuvant chemotherapy for stage IV endometrial cancer had a 92% complete cytoreduction rate [2], which was clearly higher than our reported range of 18 to 75% [1].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
